US Stock MarketDetailed Quotes
NGNE Neurogene
- 41.950
- +1.590+3.94%
Close Sep 13 16:00 ET
- 41.950
- 0.0000.00%
Post 16:01 ET
545.08MMarket Cap-14812P/E (TTM)
43.245High40.656Low88.63KVolume40.980Open40.360Pre Close3.73MTurnover1.75%Turnover RatioLossP/E (Static)12.99MShares53.00052wk High3.52P/B212.97MFloat Cap12.49052wk Low--Dividend TTM5.08MShs Float1115.000Historical High--Div YieldTTM6.41%Amplitude7.500Historical Low42.049Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Neurogene Stock Forum
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet